TrialBlood cancer journal2026

Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.

Shaji Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.